Brief: FDA Grants Catalyst Biosciences Orphan Drug Designation For Marzaa For The Treatment Of Factor VII Deficiency
28/09/2021 21:18
Sept 28 (Reuters) - Catalyst Biosciences Inc CBIO.O :
* FDA GRANTS CATALYST BIOSCIENCES ORPHAN DRUG DESIGNATION
FOR
MARZAA FOR THE TREATMENT OF FACTOR VII DEFICIENCY
Source text for Eikon: ID:nGNX35wdpj
Further company coverage: CBIO.O
Recent news on Gyre Therapeutics
See all newsBrief: Gyre Therapeutics - Enters Employment Agreement With Ying Luo As CEO - SEC Filing
Gyre Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Gyre Therapeutics, Inc. expected to post a loss of 13 cents a share - Earnings Preview
Brief: Gyre Therapeutics Reports Second Quarter 2026
Gyre Therapeutics Q2 revenue beats estimates on higher ETUARY sales volumes